India Globalization Capital, Inc. (IGC)

Our latest clients all have the potential to grow significantly in the near and long-term future

India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Mon Mar 13, 2017 4:02 pm

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC’s patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson’s, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC’s strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. “The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner,” stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers’ Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York’s Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Thu Mar 16, 2017 4:08 pm

Unique Cannabis-Pharma Companies Trailblazing the Medical Cannabis Industry

The cannabis industry has swiftly turned into a multi-billion dollar opportunity. In the United States, this market’s massive growth potential is being recognized as new states legalize marijuana for medical or recreational use. Industry experts forecast the U.S. cannabis market rounding $7 billion in 2016, while the annual sale of state-legal cannabis products is forecast to exceed $20 billion by 2020. Within this flourishing market, cannabis-pharma companies like India Globalization Capital (IGC) (IGC Profile), Zynerba Pharmaceuticals, Inc. (ZYNE), OWC Pharmaceutical Research Corp. (OWCP), Insys Therapeutics, Inc. (INSY) and GW Pharmaceuticals plc (GWPH) are carving lanes of unprecedented opportunities in the medical field.

Bethesda, Maryland-based India Globalization Capital (IGC) (IGC Profile) is advancing the development of cannabis-based therapies targeting large market conditions and illnesses. IGC is on a mission to treat chronic and terminal neurological and oncological diagnoses and other life altering conditions utilizing an exciting and specialized IP platform that formulates and tests combination therapies. With this special focus in mind, IGC has amassed a portfolio of patent filings covering the indications of pain, medical refractory epilepsy and cachexia (cancer-induced anorexia) using cannabinoids. As we will further discuss later, IGC has established an approach that significantly differentiates the company from its cannabis-pharma peers.

Like IGC, Zynerba Pharmaceuticals (ZYNE) is dedicated to the development of innovative cannabinoid treatments that target seizures and pain. Unlike IGC and Cannabics, this clinical-stage, specialty pharmaceutical company is concentrating on developing transdermal synthetic cannabinoid treatments. On March 13, 2017, the company announced that it had completed enrolling patients for Phase 2 of its STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. Zynerba also revealed that it had completed enrollment for its Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 CBD gel for the treatment of osteoarthritis.

OWC Pharmaceutical (OWCP), through its wholly owned One Word Cannabis Ltd. Israeli subsidiary, is focused on conducting medical research and pursuing clinical trials to develop cannabis-based pharmaceuticals and treatments for a variety of conditions. The company is developing two unique delivery systems to effectively dose and deliver medical cannabis. The first is a proprietary, cannabinoid-enriched sublingual tablet for the treatment of multiple myeloma, post-traumatic stress disorder, and fibromyalgia. In in-vitro testing, the tablets demonstrated 100% malignant cell death in 60% of infected mice cells. The second product is a proprietary topical compound for the treatment of psoriasis. In addition, OWC Pharmaceutical operates a Consulting Division created to help governments and companies navigate complex international cannabis regulatory frameworks.

Another industry peer, Insys Therapeutics, Inc. (INSY), is developing medications to treat addiction to opioids, opioid overdose, epilepsy and other disease areas with high unmet need. The commercial-stage company uses proprietary sublingual spray technology to develop pharmaceutical cannabinoids to address clinical shortcomings of products already on the market. Insys currently markets its FDA-approved SUBSYS® (fentanyl sublingual spray) for pain management in cancer patients who are tolerant to opioid therapy. The company has also received approval for Syndros™ for the treatment of chemotherapy-induced nausea and vomiting, as well anorexia associated with weight loss in persons with AIDS. Syndros is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (“THC”).

In terms of market share, the giant on the list of cannabis-focused biopharmaceutical companies is GW Pharmaceuticals (GWPH), which is focused on the development of plant-derived cannabinoid therapeutics based on its proprietary cannabinoid product platform. The company’s primary focus is on disorders of the central nervous system (CNS). Within this arena, GW’s lead cannabinoid product candidate is Epidiolex® (cannabidiol), in development for the treatment of rare childhood-onset epilepsy disorders. The company’s Sativex® (nabiximols) prescription drug, a therapy approved for the treatment of spasticity due to multiple sclerosis, is the world’s first plant-derived cannabinoid prescription drug. Additionally, GW boasts a deep pipeline of additional cannabinoid product candidates which includes clinical-stage compounds for glioma, schizophrenia and epilepsy.

It’s an impressive and interesting lineup, but what sets India Globalization Capital (IGC) (IGC Profile) apart from the other players is its foray into the larger market for cannabis-based combination therapies that would treat pain and other conditions. The company recently filed patents (http://nnw.fm/ggBB6) for formulations that will reduce the side effects of single drugs by being combined with a cannabinoid. IGC filed IGC-501 for a cannabis-based formulation to treat neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques.

India Globalization Capital also filed combination therapy formulations for the treatment of epilepsy/seizures (IGC-502) and cachexia (IGC-504). IGC-501, IGC-502 and IGC-503 are novel combination therapies that, if proven out by clinical trials, are expected to treat pain, medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional therapies.

Such “combination therapies” have the unique opportunity to quickly move through the FDA’s approval process, since the drugs have already been individually approved. Consequently, IGC believes it has “first mover” advantage in pursuing this approach to bring cannabis-based pharmaceutical products to market in a quick and cost-effective manner.

The cannabis industry is growing in popularity. The wave of enthusiasm surrounding the recent legalization of cannabis in several new states is sweeping the country and IGC anticipates an explosion in demand for cannabinoid-based pharmaceutical therapies, technology, facilities and financial services. With a solid strategic plan in hand, this NYSE MKT listed company has a modest $9 million market capitalization which is just a fraction of their peer group, and is aggressively leaning on its connections to medical and procedural expertise to take advantage of one of many ground-floor opportunities. And, it is developing innovative therapies, while also acquiring technologies from related industries that will place it in the right position for capitalizing on its first-mover advantage.

For more information on India Globalization Capital (IGC) please visit India Global Capital (IGC) or http://www.igcinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Tue Mar 21, 2017 6:11 pm

India Globalization Capital, Inc. (NYSE: IGC) Pioneering New Phytocannabinoid Products

Although legal in 28 states for medicinal use, cannabis is still considered a dangerous substance in much of the country. However, many experts now believe that cannabis is a safe alternative to pharmaceuticals for relieving symptoms related to multiple illnesses. Scientific research shows that phytocannabinoids, cannabinoids that occur naturally in the cannabis plant, are effective at relieving convulsions, seizures, anxiety, nausea, and inflammation. From fighting glaucoma to controlling epileptic seizures and easing pain, scientific research has repeatedly shown the efficacy of medicinal marijuana.

Due to government misclassification of cannabis as a Schedule 1 drug, there has been only marginal progress in the utilization of phytocannabinoids, which hold such promise in disease treatment and pain mitigation. Although many pharmaceutical companies still avoid association with cannabinoids, attitudes are changing, and the medicinal benefits of marijuana are being recognized for their worth.

With changes in the acceptance of medicinal marijuana, some pharmaceutical companies are finally beginning to unpack the myriad of potential benefits phytocannabinoids hold. India Globalization Capital, Inc. (NYSE MKT: IGC) is pioneering such efforts. A multi-faceted company with global experience, India Globalization has a primary focus on developing novel cannabis-based therapies for the treatment of debilitating or life threatening conditions. The company’s current pipeline of patented drugs is focused on large market maladies, including therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy, and eating disorders. Several of the company’s products are scheduled for pre-clinical trials this year.

A transformation is now underway in the medical use of cannabinoids for disease treatment, and India Globalization “believe(s) that the legalization of the cannabis industry will create an explosion in demand for cannabinoid-based pharmaceutical therapies, technology, facilities, and financial services.” With a patent portfolio of cannabinoid-based therapies, the company is well positioned for the quickly arriving time when medical cannabis gains widespread acceptance.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Tue Mar 28, 2017 5:09 pm

India Globalization Capital, Inc. (NYSE: IGC) Aims to Become a Leading Provider of Cannabis-Based Combination Therapies

India Globalization Capital, Inc. (NYSE MKT: IGC) has set a long-term goal for itself in the U.S. of becoming a leading provider of cannabis-based pharmaceutical and nutraceutical products. This is a transition away from its earlier short-term strategy, including the sale of electronics and development of a hotel site in Malaysia. To this end, the company has jettisoned its electronics business. IGC is now fully focused on building a portfolio of patents and starting clinical and pre-clinical trials for a series of pain-reducing and other cannabis-based therapies. These therapies are designed to treat neuropathic pain, seizures, Parkinson’s, anorexia/cachexia, Alzheimer’s, and PTSD.

Ram Mukunda, CEO of the company, indicated that IGC’s 2017 goals are focused on its progression toward commencement of clinical trials for these combination therapies. The Journal of Pain, in September 2012, reported that between $560 billion and $635 billion is spent annually in the U.S. for pain management, making it a significant part of the American health care system. In response, IGC has developed a series of drugs for pain and other disorders, including IGC-501 for neuropathic pain, IGC-502 for the treatment of seizures, and IGC-504 and IGC-506 for eating disorders and cachexia.

The company recently filed for issuance of a provisional patent for IGC-506, a combination of cannabis-based extracts and other compounds. It should be noted that a provisional patent does not assure the issuance of a patent in the future.

Mukunda explained that IGC is starting a review of international medical sites as the company seeks preclinical and clinical trials of its patent portfolio. He described the marketplace that IGC is entering as large, indicating that trials, patents and seeking approval from the U.S. Food & Drug Administration is seen as cost-effective.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Thu Mar 30, 2017 4:36 pm

Pain-Reducing Combination Therapies Proving Successful thanks to Innovative, Specialty Pharma Players

Combination therapies that use cannabis-based pain reduction methods without the negative side effects of opioids are looking to be a positive growth opportunity among specialty pharmaceuticals, particularly for postoperative and chronic pain relief. Leading specialty pharma companies such as India Globalization Capital, Inc. (NYSE: IGC) (IGC Profile), Cara Therapeutics, Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), and INSYS Therapeutics, Inc. (NASDAQ: INSY) are tirelessly working to expand combination therapeutics product lines, while Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) developing an opioid alternative drug intended to reduce pain after surgery.

To date, it is estimated that the annual national cost of pain is between $560 billion and $635 billion – more than priority health conditions among the nation. Sadly, the treatment of postoperative pain remains a daunting challenge for health care professionals, leaving patients debilitated in ways that can affect their daily functioning and, in turn, have a significant impact on our nation’s overall productivity. At present, patients face a significant disadvantage when using opioid drugs to treat postoperative and chronic severe pain, and usage thereof can lead to impactful side effects such as nausea, hallucinations, respiratory depression, constipation, and sedation.

While opioids have been widely accepted as a standard therapy to treat acute post-operative pain, the frequent adverse effects and burden of the cost of care has proven to be a barrier for patients who are unable to receive optimal dosing or adhered to their prescribed treatment. The administration of two opioids is not usually recommended as a treatment for moderate to severe acute pain; however, cannabis-based combination therapies present a unique opportunity in the health sector. Cannabis pharma company India Globalization Capital (IGC) has carved an impressive course in the combination therapy market as a “first mover” to combine existing drugs with cannabis. IGC recently filed a patent for a formulation that the company claims will reduce the side effects of single drugs by combining them with a cannabinoid. In particular, IGC has filed for a provisional patent for the treatment of several eating disorders that uses a combination of compounds and cannabis extracts. The combo therapy is ear-marked for both veterinary and human consumption.

After three years of building a sturdy IP portfolio, IGC is now set to obtain funding to begin both pre-clinical and clinical trials for combination therapies, for which it has started reviewing international medical facilities. Fortunately, securing FDA approval for such therapies, which include the treatment of seizures, neuropathic pain and eating disorders, tends to be swifter and less costly than applying for new drug approval. It is the company’s aim to leverage its unique first-mover position and bring its cannabis-based pharmaceuticals to market in a cost-effective and prompt manner.

Meanwhile, Pacira Pharmaceuticals (PCRX), which is collaborating with Trinity Health to develop an alternative approach to opioids for pain management, recently announced positive results for its medication for opioid reduction in a phase 4 clinical trial. During the trial, a pain regimen along with EXPAREL® was tested against a bupivacaine-based pain regimen that involved other drugs in 139 patients who were undergoing knee replacements. EXPAREL, currently used to produce postsurgical analgesia, combines bupivacaine with the DepoFoam® platform to enable the delivery of bupivacaine over a desired period of time, providing significant reductions in pain with up to a 45 percent decrease in opioid consumption.

In the phase 4 clinical trial, EXPAREL achieved statistical significance for its co-primary endpoints for postsurgical pain and opioid reduction, as well as achieved statistical significance for key secondary endpoints. In a press release announcing the results, Pacira said it continues to analyze further secondary endpoints.

Cara Therapeutics (CARA) is also working to change pain management on a fundamental level. Rather than concentrating on improving old compounds, the company is developing a new class of medicine referred to as KORAs – Kappa Opioid Receptor Agonists. This medication is aimed at targeting different receptors in the body to treat pain in an unconventional, yet more effective, manner. Up to now, Cara’s core product has shown favorable results in phase 2 clinical trials for pain relief and does not elicit the usual side effects patients would normally experience when using opioids such as hydrocodone, morphine, and non-steroidal anti-inflammatories.

Two more candidates for combination therapies come from Zynerba Pharmaceuticals (ZYNE). ZYN001 and ZYN002 are both being evaluated in various therapeutic indications at the moment. ZYN001, a pro-drug patch that comprises of THC, is aimed at enabling transdermal delivery via a person’s skin and into their circulatory system. ZYN002, a CBD gel, is the first of its kind and is designed to act as a non-psychoactive cannabinoid. The gel is to be delivered via the skin and absorbed into a patient’s circulatory system. At present, the gel is in phase 2 of clinical development with patients who suffer with osteoarthritis of the knee, refractory epilepsy, and Fragile X Syndrome.

Focused on the development and commercialization of innovative therapies that improve the quality of life of patients, Insys Therapeutics (INSY) is developing a pipeline of products intending to address unmet medical needs and clinical shortcomings of existing commercial products. The Drug Enforcement Agency recently issued a provisional final ruling that is to result in Insys’ SYNDROS™ being placed in Schedule II of the Controlled Substances Act. The product has been designed for chemotherapy patients and is aimed at helping to alleviate vomiting and nausea. It is also aimed at helping AIDS patients suffering from anorexia-type weight loss.

To date, there are some 53 million outpatients and 45 million inpatient surgeries that are performed in the United States annually. These surgeries necessitate drugs for postoperative pain, and more than half of postoperative patients continue to experience poor pain relief. At present, the therapeutic classes for postoperative pain management involve analgesics such as hydromorphone, morphine, and fentanyl, as well as NSAIDs – non-steroidal anti-inflammatories. Furthermore, the market is awash with injectable opioids that are administered either via epidural, intravenous, intrathecal, or intramuscular. Usually, the injections are administered either by patient-controlled analgesia devices or hospital personnel.

It has been found that the market for effective acute pain management in the form of combined therapies outside of the hospital setting exceeds more than 200 million prescriptions yearly. While products such as opioid analgesic combinations make up the bulk of the market, the products have significant side-effects, including sedations, dizziness, respiratory problems, substance abuse, euphoria, vomiting, and nausea. Hence, there is a vast market for combined therapies that are able to manage acute pain without producing the negative and uncomfortable side effects.

For more information on India Globalization Capital please visit India Global Capital (IGC)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Fri Mar 31, 2017 5:04 pm

India Globalization Capital, Inc. (NYSE: IGC) From Mining to Marijuana

At first blush, India Globalization Capital (NYSE: IGC) would seem a curiosity clothed in an enigma. Just how does a NYSE company move from a successful mining orientation to a pioneer in the development of multiple cannabinoid-based pharmaceutical therapies to treat pain and disease? The enigma can be disrobed by looking at the tenacity and vision of its management.

Ram Mukunda has served as Executive Chairman, CEO and President of India Global since inception in 2005. He holds distinguished mathematics and engineering degrees and worked in multiple Wall Street positions for more than 25 years, serving communications firms such as Intelsat SA and Startec. Mukunda actually founded Startec in 1991 to provide VOIP service to emerging economies. As Chairman and CEO of Startec, he led the company to a $60 million public stock offering in 1997. His introduction to the mining industry came a few years later through a company he co-founded, India Globalization Capital. The company mined and converted low-grade iron ore to high-grade ore. Iron ore prices subsequently plummeted nearly 75 percent, putting it below the cost of production. That’s when Mukunda made a difficult decision and charted a course change for the company.

Realizing that the lucrative mining business was bust, he searched for a growth arena to position the company and move forward. He ultimately centered on the burgeoning cannabis industry and the myriad of potential medical benefits. Mukunda and his team realized that there were a lot of untapped uses for cannabinoids and cannabis-based extracts. They recruited a team of highly skilled doctors and patent attorneys, comparing anecdotal stories with scientific evidence and identifying areas where patents had not been filed. This process has yielded results.

The company now has a pipeline of patent pending cannabinoid-based drugs targeting large market maladies, which includes therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy and eating disorders. Several of these therapeutic drugs are scheduled for pre-clinical trials this year. The company is transitioning fast from building research teams and developing a patent portfolio to marketable products.

For the past few years, India Globalization Capital has also focused interest on cannabis-based combination therapies, using cannabis-based extracts in combination with other medications to reduce side effects and increase bioavailability and absorption. As one of the first to enter this space, the company has been building intellectual property around these precepts and expects to reap substantial rewards from this arena.

From mining to medical marijuana would seem an incredible leap, but, when looking at India Global and the leadership of Ram Mukunda, it would be tough to bet against a leader with such tenacity and vision. And with a $12MM market cap, IGC is quite compelling given the valuations attributed to its peers.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Fri Apr 07, 2017 3:43 pm

India Globalization Capital, Inc. (NYSE: IGC) at the Forefront of Innovation Thanks to Strategic Alliances

How does a company in the mining industry successfully move toward becoming a leader in the marijuana sector, specifically cannabinoid-based pharmaceutical therapies that treat a variety of diseases and conditions? In the case of India Globalization Capital, Inc. (NYSE MKT: IGC), the answer is creative management’s ability to identify opportunity, coupled with a relentless drive toward innovation.

IGC made its switch to the marijuana industry after its CEO, Executive Chairman, and President Ram Mukunda was unafraid to recognize and act on a need for the company to make a positive and swift switch to a stronger and more lucrative market. This led IGC to cannabis and, in particular, phytocannabinoids.

The cannabis plant has a number of subspecies, some of which have psychoactive properties and others do not. Cannabis sativa is psychoactive, while other forms, such as Cannabis Sativa L., or hemp, and Cannabis ruderalis, are not. In fact, the latter offer high levels of cannabidiol, which is most commonly used on a medical level.

Legal marijuana is now becoming one of the fastest growing industries in the United States, expected to create just under 300,000 jobs for Americans by 2020 (http://nnw.fm/xM4lJ), and an increasing number of states are legalizing the drug both medically and recreationally, with the potential for further legalization on the horizon.

Although the marijuana industry is growing at an exponential rate, federal laws that classify marijuana as a Schedule 1 drug make it hard for businesses to reach their full potential,but IGC has been able to research and take advantage of cannabinoids, since these are not illegal. Part of IGC’s success is due to the fact that the company is not going about its mission to help patients suffering from pain, PTSD, seizures, and many other diseases on its own. The company is creating strategic alliances with doctors, researchers, dispensaries, and practitioners, among other industry experts, in order to develop a product portfolio of much needed phytocannabinoid-based therapies.

IGC has entered into the industry aware that there is a huge amount of information already available at the grassroots level of the marijuana industry. This is why it is seeking IP transfers with producers who know about growing hybrids and strains that are rich in specific phytocannabinoids that can be used in a pharmaceutical environment to help patients who could benefit from cannabinoids.

In addition to its extensive development pipeline, which includes six products for various disorders in both adults and animals and three expected to go through to preclinical trials this year, IGC is planning on taking equity positions within companies that are directly and indirectly part of the marijuana industry, another way that investors can take advantage of a booming industry.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Thu Apr 13, 2017 4:39 pm

India Globalization Capital, Inc. (NYSE: IGC) Plans to Develop Cannabinoid Extract Therapies for Cats and Dogs

India Globalization Capital, Inc. (NYSE MKT: IGC) intends to become a “first-mover” in developing cannabis-based combination therapies for large market conditions such as pain, eating disorders, refractory epilepsy, and seizures. In addition, IGC has filed two patents, IGC-502 and IGC-505, for combination therapies for the treatment of seizures in dogs and cats, which in it itself is a surprisingly large market.

It is believed that abnormal brain activity is the cause of most seizures in dogs and cats. These seizures can be either violent or subtle. Some seizures may occur just once, but others can be repeated and require treatment before affecting larger parts of the brain.

The pet market is large and growing. According to research by the American Pet Products Association (http://nnw.fm/0Wi4y), the market in 2017 is expected to reach $16.62 billion for veterinary care and $14.93 billion for supplies and over-the-counter medicine. By far, dogs and cats are the most popular pets. In a 2017 survey by National Pet Owners, 60.2 million American households owned a dog and 47.1 million households owned a cat.

While some of this research may also be beneficial for treating humans, it reflects IGC’s targeting of the larger veterinary market. In dogs, primary epilepsy — or idiopathic epilepsy — occurs in about 5% of the canine population (http://nnw.fm/6LTia), most often in dogs between the ages of six months and six years. In cats, seizures are much less common, occurring in only 0.5-1.0% of the population. Most are intracranial, stemming from the brain, and are epileptic in nature.

Hemp-based products for dogs, especially for older and pain-ridden dogs, are in a gray market. However, the market potential is great (http://nnw.fm/4iNu8), because it sits at the current intersection of medical pharmaceutical marijuana and pet care. Veterinarians acknowledge that legal restrictions currently impede distribution of these products in the U.S., but advances in legalization of medical marijuana may be helpful in changing the environment. For now, IGC is researching the potential of cannabis-based treatments in the pet market and developing products as this potentially represents a significant future opportunity.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Mon Apr 24, 2017 3:46 pm

India Globalization Capital, Inc. (NYSE: IGC) is a First Mover in Cannabinoid Combination Therapies

The success of the Walkman back in the 1980s is testament to the power of getting to market first. By some accounts, Sony sold over 200 million units of its innovative portable cassette player (http://nnw.fm/H6spU). Now, India Globalization Capital, Inc. (NYSE MKT: IGC) is taking a leaf from the Sony playbook. This pioneering company is a ‘first mover’ in the cannabinoid combination therapy space. IGC is developing a portfolio of products that use cannabinoids in conjunction with existing drugs to tackle chronic pain and a variety of other debilitating medical conditions.

Chronic pain from a range of ailments plagues millions around the world, and many of the analgesics employed to treat it, such as morphine, codeine, and hydrocodone, are opioids. However, opioids are notoriously addictive and their use is often subverted from pain relief. Used as recreational drugs, ‘opioid addiction is America’s 50-state epidemic’, the New York Times has reported (http://nnw.fm/8UBpU), with an effect that is fatal in many instances. According to the Centers for Disease Control (CDC), 29,000 Americans die every year from opioid-related overdoses. In light of these frightening developments, there is a growing imperative for less addictive anodynes.

The time is right. Results, published on Monday, April 17, of a Yahoo/Marist poll (http://nnw.fm/5BvcE) show that the public is not only becoming more apprehensive about opioids, but is warming to the use of cannabinoids to treat pain. ‘Two-thirds of the respondents in the telephone survey said opioid drugs such as Vicodin or OxyContin are “riskier” to use than pot, even when the pain pills are prescribed by a doctor.’ They will be happy to hear that IGC is coming to the rescue. The company has filed a patent for IGC-501, a cannabis-based formulation that addresses neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. IGC expects to begin pre-clinical trials for IGC-501 this year. Since approximately 80 percent of the global opioid supply is consumed in the United States, this presents a domestic market opportunity estimated at about $25 billion.

IGC-501, with its potential to replace treacherously addictive opioids, is not all that IGC has up its sleeve. The company has a robust portfolio of five other combination drug candidates with both human and veterinary applications. It has filed two patents, IGC-502 and IGC-505, for the treatment of seizures in dogs and cats. Most animal seizures stem from epilepsy, which is more common in dogs and cats than formerly recognized. About five percent of dogs and about one percent of cats are epileptic.

It also has IGC-503, aimed at refractory epilepsy, a term that’s used to describe cases of epilepsy that are unresponsive to current medications. Refractory epilepsy affects about 50 million in the U.S. alone. In the pipeline as well is IGC-504, intended for those who suffer from cachexia, known as wasting syndrome. About 1.3 million in the U.S. experience cachexia associated with cancer, multiple sclerosis (MS), Parkinson’s, HIV/AIDS and other devastating maladies. In addition, there is IGC-506, designed to combat eating disorders, which are said to affect about 30 million Americans (http://nnw.fm/v3LfJ).

IGC is out to save the world, it seems. Earlier this month, the company announced it had filed patent applications for IGC-501 in Canada, Israel and Europe in support of its ongoing cannabis-based combination therapy development initiatives.

“In 2017, our goal is to accelerate the development of our cannabis-based therapy portfolio to support key indications such as pain, seizures, cachexia, PTSD, and depression. In tandem, we expect to initiate pre-clinical trials on IGC-501-pain, IGC-502-seizures and IGC-504-cachexia,” CEO Ram Mukunda stated in a news release.

That is welcome news to the many millions who suffer daily from these conditions.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Wed May 03, 2017 3:51 pm

Paws Firmly Planted for Growth in Multibillion-Dollar Pet Health Market

NetworkNewsWire Editorial Coverage: Pets are the loyal, much-loved companions we humans can’t seem to live without, and when a beloved pet becomes ill, owners will generally do whatever it takes to restore these beloved companion animals to health. Various public companies are accomplishing the two-fold mission of improving the health of our four-footed friends while giving investors the opportunity to capitalize on a multibillion-dollar industry. India Globalization Capital, Inc. (NYSE: IGC) (IGC Profile), VCA, Inc. (NASDAQ: WOOF), PetMed Express, Inc. (NASDAQ: PETS), Blue Buffalo Pet Products, Inc. (NASDAQ: BUFF) and IDEXX Laboratories, Inc. (NASDAQ: IDXX) are just some of the companies blazing lucrative trails in the pet health market and successfully tapping into its virtually limitless opportunities.

In 2016 alone, U.S. consumers spent over $65 billion on pet-related products (1). According to a 2013 study published by the U.S. Bureau of Labor Statistics, U.S. households own approximately 218 million pets, and pet-related expenses for the average U.S. household amounts to about 1 percent of their total annual spending. Further, the North American Pet Health Insurance Association reports that pet health insurance premiums hit $774 million in the U.S. in 2015, with 1.6 million pets being insured by the end of that year. Clearly, consumers are interested in the health and wellbeing of their pets, and they’re showing it with dollars.

The veterinary market is a veritable cash cow – if readers will pardon the pun – that offers virtually limitless investment potential.

One pioneering company, India Globalization Capital (IGC) is forging new paths in the medical marijuana market by exploring the potential health applications of cannabis in domesticated animals. IGC is engaged in the development of phytocannabinoid-based treatments to address pain and a variety of medical conditions, including marijuana-based therapies to treat seizures in dogs and cats.

Treatment for pet seizures represents a surprisingly large market. Statistics indicate that between 1 percent and more than 5 percent of dogs have some sort of seizure disorder, and certain canine breeds with hereditary epilepsy may have as high as 15 to 20 percent incidence of seizures. Abnormal brain activity is frequently the culprit behind canine and feline seizures, and these seizures can result in both subtle and violent convulsions, either of which is most alarming for a pet owner to witness.

IGC offers a novel therapy using cannabinoid extracts to treat such seizures in pets. The company has applied for a U.S. patent based on this therapy, which can be administered via various delivery technologies and has indications for mammals, including dogs and cats. This therapy has the potential to be useful in humans, as well. IGC anticipates conducting metabolic profiling and commencing trials.

Another company aimed at capitalizing on the opportunities of the pet health market is VCA (WOOF). This veterinary services company has become one of the largest families of animal care providers in the United States, operating more than 800 veterinary hospitals across the U.S. and in five Canadian provinces. The company also provides diagnostic services and supplies high-tech imaging to over 17,000 independent veterinary hospitals. Through its Camp Bow Wow subsidiary, VCA additionally provides doggy daycare and boarding services at more than 130 franchised locations throughout the United States.

Online pet pharmaceutical company PetMed Express (PETS), also known under the name 1-800-PetMeds, is the largest pet pharmacy in America, having served over 9 million customers and counting. PetMeds is a licensed pharmacy that dispenses FDA/EPA-approved medications for animals—the same products available from veterinarians—and employs the largest number of veterinary pharmacists in the world.

Blue Buffalo Pet Products (BUFF) approaches pet health in another way, offering natural, healthy pet foods to help prevent—and in some case treat—pet illness and to foster the health of America’s pets in a nutrition-based way. The company currently has approximately 6 percent share of the general pet food industry, feeding 164 million pets in the U.S. and counting. The company’s products include veterinarian- and nutritionist-formulated therapeutic pet foods that can only be purchased through veterinary offices.

Pet health care innovator IDEXX Laboratories (IDXX) serves veterinarians across the globe with a wide array of diagnostic and information technology-based services and products. These products better equip and enable veterinarians to offer advanced medical care, bolster staff efficiency, and build practices that are more economically successful. The company is also a leading global provider of diagnostic tests and information for livestock and poultry, as well as tests that gauge the quality and safety of water and milk. Among its products, IDEXX offers the very first low-dose radiography system in veterinary medicine, as well as a test that enables veterinarians to detect acute kidney injury and chronic kidney disease in pets earlier than ever before. IDEXX Laboratories products are sold in over 175 countries.

It’s no secret that consumers love their pets, and a multibillion-dollar global industry is positive proof. Companies, such as those named, that are in the business of serving the health interests of pets provide a virtually limitless wellspring of investment opportunities in a market that is ever-growing and boasts impressive longevity to rival any other market segment in existence.

For more information on India Globalization Capital please visit India Global Capital (IGC)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Thu May 04, 2017 4:46 pm

India Globalization Capital (NYSE: IGC) Strategically Staking Claims in the Medical Marijuana Markets

In a testament to its medical efficacy, 29 states and the District of Columbia have now legalized medical marijuana. This groundswell with state sanction and now widespread public acceptance has started a stampede of companies jockeying to profit from legalization. From the sale of oils and extracts to specialized cultivation, multiple companies are rushing into this new market hoping to cash in on surging demand. However, rushing in just might not be the right approach to making real money in this sector.

There’s an old adage that says the way to create real wealth is to find out where everyone is going, get there first and buy real estate. Utilizing a strikingly similar approach, one interesting company is strategically staking claims to medicinal marijuana territory. India Globalization Capital (NYSE MKT: IGC) formerly mined and converted low-grade iron ore to high-grade ore until prices plummeted. It was then that company management made the decision that to preserve shareholder value it must change course. As a result, IGC entered the burgeoning medical marijuana market. It’s estimated that sales in the cannabidiol (CBD) market, the medicinal non-euphoric part of cannabis, will grow 700 percent to nearly $3 billion annually by 2020. That kind of explosive growth is certain to attract multiple pretenders to the throne.

With decades of Wall Street experience, IGC management knew better than to just rush into the feeding frenzy. Instead, the company took a deliberate, judicious approach to market opportunity. Realizing that therapeutic cannabidiol treatments essentially comprised new drug formulations, IGC assembled a team of highly skilled physicians and researchers to compare anecdotal efficacy with scientific evidence and identify areas where cannabidiol therapies could have significant impact in large market maladies. The company then engaged experienced pharmaceutical patent attorneys to protect these new intellectual properties and now has a pipeline of patent pending cannabinoid-based drugs to treat neuropathic pain, human and animal seizures, refractory epilepsy, and eating disorders. Several of these novel therapeutics are scheduled for pre-clinical trials this year.

Focused on expanding its patent portfolio in the CBD space, India Globalization Capital is among the very first to stake claims in cannabis-based combination therapies. The company has been building intellectual properties surrounding the combined use of cannabis-based extracts with other medications to reduce side effects and to increase bioavailability and absorption. To further its reach, IGC also intends to take equity positions in ancillary cannabis businesses and is aggressively seeking partnerships with other scientifically based cannabinoid researchers, as well as with producers and processors holding intellectual properties in particular cannabidiol strains that can be proved up for pharmacological use.

With its scientific approach to new drug formulation protected with multiple patents, IGC is strategically staking out incredibly valuable territory in the new frontier of cannabidiol therapeutics. The company’s expanding IP portfolio and low market capitalization present a compelling investment opportunity in the CBD space. As curative phytocannabinoid treatments expand exponentially, India Globalization Capital is well positioned to reap substantial rewards for getting there early and owning patent protected turf in the medicinal marijuana sector.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Fri May 05, 2017 4:08 pm

India Globalization Capital, Inc. (NYSE: IGC) Engages a Critical Point in Cannabis History

Cannabis is now legal medically or recreationally in 28 states in the U.S., and companies such as India Globalization Capital, Inc. (NYSE MKT: IGC) are developing revolutionary cannabinoid-based combination pharmaceutical therapies. Cannabis’ history doesn’t begin in the 1960s. Scientists have dated burned cannabis seeds found in Siberia to 3,000 B.C., and mummified psychoactive marijuana has been found in tombs of individuals buried around 2,500 B.C. Fast forward a few thousand years and add laws, regulations, and cultural stigma, and behold one of the most disputed substances. In the 1850s, recreational cannabis was considered fashionable in the U.S., and it was widespread in the 1920s as well. In 1937, Congress passed the Marijuana Tax Act, making it illegal to possess and transfer cannabis. The Controlled Substances Act (CSA), passed in 1970, lists cannabis as a high-abuse-potential Schedule 1 drug.

Although the CSA hasn’t been changed, marijuana has been decriminalized in many places. Medical cannabis was legalized in California in 1996, and Alaska, Oregon, Washington, and Arizona followed suit in 1998. The trend has accelerated, and, by 2011, additional states were favoring medical cannabis or passed legislation to decriminalize it. These included Nevada, Colorado, Massachusetts, New Jersey, Connecticut, and Washington D.C. Even more impressive than the territory covered by jurisdictions allowing cannabis and cannabis-related products is the multi-billion-dollar industry that’s emerged and promises to keep on growing.

Ram Mukunda, executive chairman, CEO, and president of India Globalization Capital, has taken the company on a course that is as impressive as the cannabis industry itself. IGC was founded in 2005 to mine iron ore. Once the prices for iron ore plummeted, Mukunda took the company in a different direction to focus on the untapped potential of cannabinoids and cannabis-based extracts.

Today, the company’s pipeline of patent-pending cannabinoid-based compounds represents treatment for a number of large market conditions. Cannabis-based pain medications are in development, providing opportunities for investors, as are drugs for post-traumatic stress disorder, Alzheimer’s disease, Parkinson’s disease, and depression. Therapeutic drugs for treating seizures in humans and animals are in development as well.

The company’s drug development pipeline consists of a cream/patch for treating neuropathic pain, eating disorder treatments for adult and veterinary use, and a refractory epilepsy drug for adults. Pre-clinical trials are anticipated in 2017 for three of IGC’s combination therapy compounds. The company has come a long way from running mining operations to developing high potential phytocannabinoid-based treatments, but it is now helping to shape a critical point in cannabis history as medical use becomes more mainstream.

To learn more about India Globalization Capital, Inc., its drug development pipeline, and other cannabinoid- and cannabis-related initiatives, visit the company online at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Mon May 08, 2017 3:25 pm

India Globalization Capital, Inc. (NYSE: IGC) Positioned to Lead in Phytocannabinoid Pharmaceuticals

A study recently highlighted by the American Epilepsy Society (AES) at its 70th annual meeting focused on the potential of cannabidiol (CBD), a derivative of the cannabis plant, as a promising treatment for reducing both the frequency and severity of seizures in children with drug resistant epilepsies (http://nnw.fm/u3xAh). According to the study, patients who received CBD treatment exhibited over 45 percent mean reduction in seizures, and researchers were outspoken in support of further research.

Cannabidiol is the most abundant non-psychoactive cannabinoid found in the cannabis plant. Both anecdotal evidence and pre-clinical research have suggested that CBD may have a broad range of beneficial therapeutic uses in humans and animals including pain mitigation, epileptic seizures and wasting disease eating disorders (cachexia). Animal studies have also shown promise for CBD’s anticonvulsant efficacy in multiple species (http://nnw.fm/NDKi2).

As referenced in a recent article (http://nnw.fm/hm4MT), multiple companies compete in the $65 billion diverse pet product market, with about $15 billion spent on veterinary care annually in the United States. Seizures afflict about five percent of the 90 million dogs in the U.S. and a little over two percent of the 94 million felines. The most commonly used drugs to treat pet seizures include a lifetime regimen of phenobarbital, potassium bromide, and diazepam. India Globalization Capital, Inc. (NYSE MKT: IGC) is changing the paradigm of seizure treatments for dogs and cats based on its novel patent pending therapy using cannabinoid extracts.

India Globalization Capital is actually building a broad portfolio of multiple intellectual properties around the utilization of phytocannabinoid-based therapies in both animals and humans. The company is at the forefront of the combined use of cannabis-based extracts with other medications to reduce side effects and to increase bioavailability and absorption (phytocannabinoid-based combination therapy).

IGC has developed a pipeline of patent pending cannabinoid-based drugs targeting large market disorders such as therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy and eating disorders. Several of these therapeutic compounds are scheduled for pre-clinical trials this year. With a team of experts encompassing patent law, clinical trials and regulatory procedures, IGC is positioned to become a leader in specialty pharmaceuticals and offers an interesting opportunity to profit from this exciting new market.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Thu May 11, 2017 6:19 pm

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Poised to Become Phytocannabinoid Pharmaceuticals Leader

At its recent 70th annual meeting, the American Epilepsy Society (AES) highlighted a study focusing on the potential of cannabidiol (CBD) to treat the frequency and severity of seizures in children who have drug-resistant epilepsies. India Globalization Capital (NYSE MKT: IGC), an innovator in developing cannabis-based combination therapies to treat pain and other conditions, is currently applying the revolutionary seizure-treating potential of CBD to another population: domestic pets, and the company is addressing the 5 percent of dogs and just over 2 percent of cats in the United States that experience seizures. “Cannabidiol is the most abundant non-psychoactive cannabinoid found in the cannabis plant. Both anecdotal evidence and pre-clinical research have suggested that CBD may have a broad range of beneficial therapeutic uses in humans and animals including pain mitigation, epileptic seizures and wasting disease eating disorders (cachexia). Animal studies have also shown promise for CBD’s anticonvulsant efficacy in multiple species.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Tue May 16, 2017 5:02 pm

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adds Craig Cheifetz, M.D. to Advisory Team

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that Craig Cheifetz, M.D. has joined the company as an advisor to provide guidance on clinical trials, biotechnology, neuroscience, immunology and microbiology. “I welcome Dr. Cheifetz to the IGC advisory team and look forward to his contributions as we move forward in developing cannabis-based, combination therapies,” Ram Mukunda, CEO of IGC, stated in the news release. “We remain committed to accelerating our initiatives and building a robust portfolio of compounds to address large market conditions.” Cheifetz currently serves as Regional Dean at Virginia Commonwealth University Inova Fairfax Campus and Medical Director of Inova VIP 360, North Virginia’s premier concierge medicine program. He received his M.D. from the State University of New York College at Buffalo and trained in Internal Medicine at Georgetown University.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Wed May 17, 2017 5:30 pm

Cannabis-Based Therapies with Potential to Dull the Pain of Opioid Abuse

NetworkNewsWire Editorial Coverage: America is in an opioid epidemic. On an average day, 91 Americans will die from an opioid-related overdose. That’s according to the CDC, which also reports that the number of prescription opioids sold in the U.S. has nearly quadrupled since 1999 despite no overall change in the amount of pain reported. The result is more than half a million deaths by opioid overdose from 2000 to 2015. These sobering figures reveal the desperate need for opioid substitutes, and cannabis-based therapies for pain treatment are emerging as viable alternatives. The potential rewards are significant for companies that can develop these therapies, and among those growing in recognition are India Globalization Capital, Inc. (IGC) (IGC Profile), Vitality Biopharma, Inc. (VBIO), Cara Therapeutics, Inc. (CARA), Zynerba Pharmaceuticals, Inc. (ZYNE) and AXIM Biotechnologies, Inc. (AXIM).

According to a 2016 report published by Transparency Market Research, analysts surmise that almost 20 percent of the world’s population currently suffers from chronic pain (1). As such, the global pain management therapeutics market is expected to exhibit a 3.7 percent CAGR through 2024, with market valuation increasing to US $83.0 billion by the same year.

A closer look at chronic pain explains this growth. Terminal illness, for one, is frequently accompanied by pain so agonizing, severe, and difficult to treat that death can seem like a preferable option to the patient. A key disadvantage of currently available drug therapies for chronic severe pain is that opioid-based drugs can create various side effects, including hallucinations, sedation, nausea, respiratory depression, constipation and dysphoria. Pain treatment also poses a significant challenge to health care professionals because it frequently debilitates patients in ways that hamper their day-to-day functionality, which, by extension, poses a huge productivity problem among U.S. citizens. In 2012, the annual cost of pain in the United States was estimated at between $560 billion and $635 billion—eclipsing the costs of national priority health conditions.

In light of this information, imagine for a moment the inconceivable potential of a cannabis-based combination therapy that could effectively address a large market indication. An achievement of this sort would propel an undiscovered stock straight into the spotlight. Such is the case and possibility with India Globalization Capital (IGC).

IGC aims to formulate and commercialize cannabinoid compounds as an alternative to addictive long-term opioid treatments, endeavoring to do so through a focus on combination therapy. The company is developing a portfolio of phytocannabinoid-based therapies to treat a broad range of therapeutic indications, including neuropathic and cancer pain. IGC has applied for a U.S. patent to treat pain based on a novel therapy that utilizes cannabinoid extracts. This therapy employs a cream that is applied through the use of various delivery technologies and has indications in both humans and other mammals, including dogs and cats. The company plans to conduct metabolic profiling and to run trials in the near term. IGC’s patent filing (IGC-501) is a cannabis-based formulation that addresses neuropathic and arthritic pain via various delivery techniques.

IGC’s innovative and exciting strategy is to leverage its “first mover” position to become a leader within the phytocannabinoid-based combination therapy specialty pharmaceutical sector. Developing cannabis-based combination therapies represents a huge and unique opportunity in this emerging specialty pharmaceutical sector. Obtaining FDA approval for combination therapy is typically significantly quicker and less costly than new drug applications, which means IGC can potentially bring its cannabis-based pharmaceutical products to market in a timely and thus cost-effective manner. With a market cap of approximately $11.0 million, a fraction of that of its peer group, IGC is poised to explode once its cannabis-based pain therapies obtain approval and can be brought to the market.

Another company taking aim at bringing cannabis-based therapies to market is Vitality Biopharma (VBIO), which has a market cap of approximately $51.7 million. A cure development company, Vitality Biopharma is focused on utilizing cannabinoid “prodrugs” to treat serious neurological and inflammatory disorders and to provide targeted therapies with the potential to offer long-term or durable relief and possibly help patients recover lost function.

Prodrugs are compounds or medications that, upon administration, are converted inside the body into a pharmacologically active drug that may already have a lengthy history of clinical investigation and use. As reference drugs may already have independent verification of their safety and effectiveness, some prodrugs can potentially be quickly approved by demonstrating comparable bioavailability or bioequivalence. A prodrug can simultaneously be much more marketable because of its ability to eradicate undesirable side effects or commercial aspects.

As public interest in medical marijuana applications continues to increase, clinical trials sponsored by academic investigators for using cannabinoids in the treatment of profitable, large-market disease indications is also increasing. Vitality Biopharma’s ability to quickly create proprietary prodrug versions of CBD, THC, CBVD and others positions the company to benefit from emerging data and increasing medical community recognition of the potential pain relief and anti-inflammatory effects of cannabinoids. It has become a well-established fact that cannabis has the potential to provide relief of pain and inflammation in certain disease indications, and Vitality Biopharma’s prodrugs have the potential to exert the same positive therapeutic effects as current therapies, with noteworthy improvements. Vitality Biopharma has filed intellectual property applications and is seeking global patent protection through 2035 with strong composition matter claims for prodrugs of THC, CBD and CBDV, as well as for the company’s proprietary prodrug biosynthesis platform that utilizes enzymatic glycosylation.

Another company applying the medical properties of cannabis for the treatment of pain is Cara Therapeutics (CARA), with a market cap of approximately $539.6 million. Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities, which are designed to lessen pain and pruritus by selectively targeting peripheral kappa opioid receptors. The company is developing a novel and proprietary class of product candidates designed to target the peripheral nervous system of the body and that have shown initial efficacy in patients suffering with moderate-to-severe pain. This has been demonstrated without creating many of the unwanted side effects that are normally associated with current pain therapeutics.

Studies conducted to assess the effects of cannabis have led to a recent discovery of an endogenous system of ligands within humans that are involved in various physiological processes, including pain and inflammation. The primary naturally occurring ligands for this system activate numerous cannabinoid receptors, including CB1 and CB2 receptors. CB1 receptors and associated ligands are primarily localized in the brain, while CB2 receptors are chiefly found in peripheral tissues—in particular immune cells like leukocytes and mast cells, which have been shown to have involvement in pain and inflammatory responses. Cara Therapeutics is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. The company will initially develop peripheral CB receptor modulators as a novel therapeutic approach for neuropathic pain. CR701, the company’s most advanced CB compound, is currently in preclinical development.

Zynerba Pharmaceuticals (ZYNE), with a market cap of approximately $255.8 million, is also seeking to treat a variety of severe health conditions, including peripheral neuropathic pain—in this case by applying synthetic cannabinoid therapeutics that are formulated for transdermal delivery. A clinical-stage pharmaceutical company, Zynerba Pharmaceuticals currently has two lead product candidates in its development pipeline: ZYN002 and ZYN001. These product candidates are being evaluated in five therapeutic indications. ZYN002 is the first and, currently, the only synthetic CBD, which is a non-psychoactive cannabinoid. It has been formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin into the body’s circulatory system and is in phase 2 clinical development. ZYN001 is a prodrug of THC that facilitates transdermal delivery through the skin and into the circulatory system through a patch. A phase 1 clinical trial of ZYN001 is planned to commence in 2017.

AXIM Biotechnologies (AXIM), with a market cap of approximately $410.5 million, is focused on the research, development and production of cannabinoid-based pharmaceutical products and supplements. The company owns the patent for the use of chewing gum as a cannabinoid delivery method, and its MedChew RX gum will soon commence phase 3 clinical trials for the treatment of pain and spasticity related to multiple sclerosis. This pharmaceutical, functional chewing gum contains equal portions of THC and CBD. Thanks to the company’s proprietary technology, various problems related to the water insolubility of cannabinoids have been addressed and resolved. Based on AXIM’s proprietary intellectual property, a new direct and controlled slow-release nano-technology delivery method is planned to be investigated. Various other R&D projects are also being considered that involve AXIM’s proprietary intellectual property.

There is no denying the power and potential of cannabis-based therapies for pain management, and investors have the opportunity to scout the playing field of this market to identify the most promising companies. This growing segment of the health care field increasingly demonstrates favorability by addressing key health issues that affect people in the United States and around the world.

Sources:
(1) Transparency Market Research http://nnw.fm/uL54B

For more information on India Globalization Capital visit India Globalization Capital (IGC)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Thu May 18, 2017 3:39 pm

India Globalization Capital, Inc. (NYSE: IGC) is Blazing a Trail with its Cannabis Plus Therapies

Slowly but surely cannabis is losing the stigma that has plagued it for close to one hundred years. Even some who frown on its use for recreational purposes are willing to consider that there may be therapeutic benefits in extracts of the cannabis sativa plant and so, increasingly, cannabinoids are being investigated to determine their effectiveness to treat a variety of debilitating medical conditions. Cannabinoid pharma is emerging as an entirely new industry segment in pharmaceuticals, and, as it does so, one innovative research company is blazing a trail in this new market by creating a niche of its own. India Globalization Capital, Inc. (NYSE MKT: IGC) has created its own space in pharmaceuticals. The Bethesda, Maryland-based company is a first mover in “combination therapies” that merge cannabinoids with existing drugs to provide more effective remedies.

IGC is not only a first mover in combination therapies; the company is also a fast mover. To date, IGC has dispatched six provisional patent filings to the U.S. Patent and Trademark Office for the indications of pain, medical refractory epilepsy, seizures, cachexia and eating disorders. Together, the remedies for these conditions present huge market opportunity, and IGC’s current low valuation versus comparable cannabis companies represents an important alert for all investors in this burgeoning industry.

IGC-501 is being developed to combat pain. The pain market represents a significant component of the health care system, with The Journal of Pain reporting in September 2012 that the annual estimated national cost of pain ranges from $560 billion to $635 billion, a figure that exceeds the cost of treating all other priority health conditions. Also, a NetworkNewsWire report on data released by Transparency Market Research estimates the global pain management therapeutics market will have a 3.7 percent CAGR through 2024, to reach $83.0 billion (http://nnw.fm/it5tO).

Chronic pain takes such an exacting toll on the nation’s health that the American Pain Society has recommended pain be characterized as a fifth ‘vital sign’, along with body temperature, pulse rate, respiratory rate and blood pressure. Pain treatment can save lives. Terminal illnesses are often accompanied by levels of pain so intense and difficult to treat that death seems preferable. In addition, arthritis has been particularly problematic for women, according to the Arthritis Foundation, which reports that since 1999 there has been a 22 percent increase in the number of women who attribute their disability to arthritis.

As awareness of the effects of chronic pain has grown, increasingly powerful drugs such as morphine, codeine, and hydrocodone are being prescribed. However, these opioids are treacherously addictive and their use is often subverted from pain relief, making their way into recreational use. According to the Centers for Disease Control (CDC), 29,000 Americans die every year from opioid-related overdoses. This alarming statistic shows the pressing need for less addictive analgesics like IGC-501.

IGC-503 tackles refractory epilepsy, which affects about 50 million in the U.S. alone. Refractory epilepsy refers to cases of epilepsy that are unresponsive to current medications. Also in the pipeline is IGC-504, intended for those who suffer from cachexia, known as wasting syndrome. About 1.3 million in the U.S. experience cachexia associated with cancer, multiple sclerosis (MS), Parkinson’s, HIV/AIDS and other devastating maladies. In addition, there is IGC-506, designed to combat eating disorders, which are said to affect about 30 million Americans (http://nnw.fm/W0ts2). Two other patents, IGC-502 and IGC-505, are designed to treat epileptic seizures in dogs and cats.

On the release of its financial results for the third-quarter ended December 31, 2016, CEO Ram Mukunda stated, “In 2017, our goal is to accelerate the development of our cannabis-based therapy portfolio to support key indications such as pain, seizures, cachexia, PTSD, and depression. In tandem, we expect to initiate pre-clinical trials on IGC-501-pain, IGC-502-seizures and IGC-504-cachexia.”

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Mon May 22, 2017 4:23 pm

India Globalization Capital, Inc. (NYSE: IGC) Developing Phytocannabinoid-Based Product Pipeline to Treat Two- and Four-Legged Alike

Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals. The company’s focus is on treating pain, post-traumatic stress disorder (PTSD), chronic and terminal neurological and oncological diagnoses, cachexia, and other life-altering medical conditions.

IGC continues developing a portfolio of patent filings for phytocannabinoid-based treatments and has filed six patents to date. The company currently has three products in pre-clinical trials: IGC-501 for treatment of neuropathic pain in adult humans, IGC-502 for treatment of seizures in animals, and IGC-504 for treatment of cachexia in humans and animals.

Two of IGC’s patent filings, IGC-502 and IGC-505, are for combination therapies to treat seizures in dogs and cats, which represents a remarkably large market. Statistics show that between one percent and over five percent of dogs in the United States have some kind of seizure disorder. Certain dog breeds with hereditary epilepsy may have up to 15-20 percent incidence of seizures.

IGC’s novel therapy uses cannabinoid extracts in combination with other drugs to treat seizures in both dogs and cats, and this therapy has potential for application in humans, as well. The therapy can be administered through a variety of delivery technologies.

Operating on the belief that expanding cannabis legalization will create explosive demand for cannabinoid-based pharmaceutical therapies and related technologies and services, IGC is racing to be at the head of the pack and to be a first mover in the marijuana space by developing novel therapies, filing patent applications, and acquiring technologies from related industries that can cross over to cannabis as soon as permitted by federal law.

The company largely employs an outsourced model and has formed strategic alliances with doctors and scientists with expertise in central and peripheral nervous system disorders, the FDA process, and in pharmaceutical, nutraceutical and veterinarian trials. IGC also continues seeking information exchanges with medical cannabis dispensaries, doctors, research scientists, biotech companies, and medical and business professionals within the cannabinoid space, placing great value on collaborative research that can aid in the commercialization of products and in locating new ways to help patients — both human and animal — benefit from cannabinoids.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Wed May 24, 2017 5:27 pm

India Globalization Capital, Inc. (NYSE: IGC) Taps Dr. Craig Cheifetz as Advisor for Clinical Trials of Cannabis-Based Combination Therapies

India Globalization Capital, Inc. (NYSE MKT: IGC) has named Craig Cheifetz, M.D., as an advisor to aid the company in its clinical trials in microbiology, immunology, neuroscience, and biotechnology. IGC is engaged in the development of cannabis-based therapies, which treat pain, terminal neurological and oncological diagnosis, PTSD, seizures, and other life altering issues. The company, based in Bethesda, Maryland, has a portfolio of patent filings for its phytocannabinoid-based treatments.

In a news release, Ram Mukunda, CEO of IGC, welcomed Cheifetz to the company’s advisory team, noting that he looks forward to Chiefetz’s contributions as IGC develops unique cannabis combination therapies.

Cheifetz is the Medical Director of Inova VIP 360, Northern Virginia’s Concierge Medicine Program. He is also Regional Dean at Virginia Commonwealth University Inova Fairfax Campus.

He received his M.D. from the State University of New York at Buffalo and also attended Georgetown University, where he trained in internal medicine. He was National GRMC Chairman from 2011 to 2013.

“We remain committed to accelerating our initiatives and building robust a portfolio of compounds to address large market conditions,” Mukunda noted in the release.

The company anticipates clinical trials in 2017 for several indications, including pain, a huge market. IGC has already filed for six patents in areas such as eating disorders and epilepsy, in addition to pain. It is working on several more filings for indications including depression, Alzheimer’s and Parkinson’s disease. Its lead candidate is IGC-501, and it has filed patents for the candidate in the United States, Canada and Europe.

For more information, visit the company’s website at www.IGCinc.us
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: India Globalization Capital, Inc. (IGC)

Postby QualityStocks » Thu May 25, 2017 4:59 pm

IGC Executive Summary Available

$IGC Executive Summary is Now Available Online:
http://www.networknewswire.info/igc/exe ... summary/#1
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 440
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Next

Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 1 guest

cron